<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331642</url>
  </required_header>
  <id_info>
    <org_study_id>BG05/2011</org_study_id>
    <nct_id>NCT01331642</nct_id>
  </id_info>
  <brief_title>Biomarker for Gaucher Disease</brief_title>
  <acronym>BioGaucher</acronym>
  <official_title>Biomarker for Gaucher Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gaucher disease is an autosomal recessive hereditary lysosomal storage disorder. Occurrence
      of the disease is due to a hereditary deficiency of the Glucocerebrosidase, a lysosomal
      enzyme which divides Glucocerebroside in to Glucose and Ceramides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The unmetabolised Glucocerebrosides are stored throughout the whole reticulo-endothelial
      system. Accumulation of Glycolipid-enriched Macrophages establishes a pathoanatomical
      phenomenon, the so-called Gaucher cells, which can be verified by light microscopy.
      Activation markers of the Macrophages, like the enzyme Chitotriosidase or CCL18, are
      parameters which follow the course of Gaucher dis-ease. Gaucher disease is the most
      frequently inherited Sphingolipidosis in the general population, and in Ahskenazi Jews, in
      who the prevalence is much higher (1:450). The gene which codes the Glucocerebrosidase is on
      the long arm of chromosome 1 and covers 11 exons. So far, more than 200 different mutations
      in Gaucher patients have been described, mostly missense mutations. In addition frame-shift-
      and splice-site-mutations have been detected, as well as insertions and deletions. More
      frequent mutations are N370S, L444P, IVS2+1G&gt;A, c.84insG, R463C and R496H [Sidransky E.
      2004]. The clinical appearance is heterogeneous. The classical phenotype is characterized by
      visceral organ (Hepatosplenomegaly) and skeleton system (Bone marrow infiltrates up to bone
      infarcts and pathological fractures) affection. Moreover, consecutive blood cell count
      changes, Anemia and Thrombocytopenia are reported.A serious distinction lies in the
      appearance of neurological manifestations (myoclonus epilepsy, hydrocephalus, ocular movement
      disturbances). There is discussion on whether the classification into the typical three
      disease types (type1: non-neuronopathic progress form, type2: acute neuronopathic progress
      form, type3: chronic neuronopathic progress form) is still up-to-date, since it does not
      sufficiently reflect the reality of the clinical presentation. A clear genotype-phenotype
      relationship does not exist. The same DNA mutations are detected in patients with pronounced
      differences in disease progression. The exception is the mutation N370S, which has so far
      been detected in connection with only visceral progress forms (type1) [Koprivica et al.
      2000]. At least the outcome of the non-neuronopathic disorder cases could be improved by the
      introduction and general availability of enzyme therapy. Under this kind of therapy there is
      a reduction of liver and spleen size as well as a normalization of the haemogram parameters.

      New methods, like mass-spectrometry give a good chance to characterize in the blood (plasma)
      of affected patents specific metabolic alterations that allow to diagnose in the future the
      disease earlier, with a higher sensitivity and specificity. The development of new
      bio-chemical markers from the plasma of the affected patients is the goal of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of a new MS-based biomarker for the early and sensitive diagnosis of Gaucher Disease from plasma</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing for clinical robustness, specificity and long-term stability of the biomarker</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Gaucher Disease</condition>
  <condition>Sphingolipidoses</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients from the first day of life with Gaucher Disease based on biochemical and/or genetic criteria or high-grade suspicion for Gaucher disease.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For the development of the new biomarkers using the technique of Mass-spectometry 5ml EDTA
      blood and a dry blood spot filter card are taken. To proof the correct Gaucher diagnosis in
      those patients where up to the enrollment in the study no genetic testing has been done,
      sequencing of Gaucher will be done. The analyses are done in the Albrecht-Kossel-Institute
      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Gaucher Disease based on biochemical and/or genetic criteria or high-grade
        suspicion for Gaucher disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent will be obtained from the patient or the parents before any study
             related procedures.

          -  Patients from the first day of life

          -  The patient has a diagnosis of Gaucher Disease based on biochemical and/or genetic
             criteria or high-grade suspicion for Gaucher disease

        High-grade suspicion present, if one or more inclusion criteria are valid:

          -  Positive family anamnesis for Gaucher disease

          -  Splenomegaly without identifiable cause

          -  Hepatomegaly without identifiable cause

          -  Anemia or thrombocytopenia without identifiable cause CNS involvement without
             identifiable cause

        Exclusion Criteria:

          -  No Informed consent from the patient or the parents before any study related
             procedures

          -  No diagnosis of Gaucher disease or no valid criteria for profound suspicion of Gaucher
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Rolfs, MD</last_name>
    <phone>+49 381 494</phone>
    <phone_ext>9540</phone_ext>
    <email>arndt.rolfs@med.uni-rostock.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Zielke</last_name>
    <phone>+49 381 494</phone>
    <phone_ext>4739</phone_ext>
    <email>susanne.zielke@med.uni-rostock.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric practice</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <email>benmansour_b@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Technology Assessment in Clinical Genetics Research Group</name>
      <address>
        <city>Porto Alegre -RS</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ida Vanessa Schwartz, Prof</last_name>
      <email>idadschwartz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ida Vanessa Schwartz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinics Hospital of Ribeirao Preto- University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Marques Lourenco, MD</last_name>
      <email>charlesgenetica@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Charles Marques Lourenco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rostock, Albrecht-Kossel Institute</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Zielke</last_name>
      <phone>49-381-494</phone>
      <phone_ext>4739</phone_ext>
      <email>susanne.zielke@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Arndt Rolfs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki-Ippokration General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <email>jeff@med.auth.gr</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIRMAN, University of Mumbai</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jalan, MD</last_name>
      <email>jalananil@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anil Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Health Institute of Serbia</name>
      <address>
        <city>Novi-Beograd</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrijan Sarajlija, MD</last_name>
      <email>adrijans2004@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrijan Sarajlija, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Arndt Rolfs</investigator_full_name>
    <investigator_title>Prof. Dr. Arndt Rolfs</investigator_title>
  </responsible_party>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Lipidoses</keyword>
  <keyword>Lipid Metabolism, Inborn Errors</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Sphingolipidoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

